INDAPTUS THERAPEUTICS INC (INDP) Stock Price, Forecast & Analysis
NASDAQ:INDP • US45339J2042
INDP Key Statistics, Chart & Performance
The current stock price of INDP is 2.02 USD. In the past month the price decreased by -28.7%. In the past year, price decreased by -90.98%.
INDP Technical Analysis
INDP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to INDP. INDP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
INDP Financial Highlights
Over the last trailing twelve months INDP reported a non-GAAP Earnings per Share(EPS) of -31.67. The EPS increased by 34.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -246.6% | ||
| ROE | -366.23% | ||
| Debt/Equity | 0 |
INDP Forecast & Estimates
7 analysts have analysed INDP and the average price target is 10.2 USD. This implies a price increase of 404.95% is expected in the next year compared to the current price of 2.02.
INDP Ownership
INDP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 396.512B | ||
| AMGN | AMGEN INC | 16.63 | 202.199B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.492B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 119.063B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.713B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.834B | ||
| INSM | INSMED INC | N/A | 34.336B | ||
| NTRA | NATERA INC | N/A | 30.104B | ||
| BIIB | BIOGEN INC | 12.62 | 28.19B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.691B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About INDP
Company Profile
Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2012-09-07. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The firm's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
Company Info
INDAPTUS THERAPEUTICS INC
3 Columbus Circle, 15th Floor
New York City NEW YORK US
CEO: Jeffrey A. Meckler
Employees: 7
Phone: 13024853907
INDAPTUS THERAPEUTICS INC / INDP FAQ
Can you describe the business of INDAPTUS THERAPEUTICS INC?
Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2012-09-07. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The firm's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
What is the current price of INDP stock?
The current stock price of INDP is 2.02 USD. The price increased by 9.78% in the last trading session.
What is the dividend status of INDAPTUS THERAPEUTICS INC?
INDP does not pay a dividend.
What is the ChartMill rating of INDAPTUS THERAPEUTICS INC stock?
INDP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for INDP stock?
7 analysts have analysed INDP and the average price target is 10.2 USD. This implies a price increase of 404.95% is expected in the next year compared to the current price of 2.02.
What is INDAPTUS THERAPEUTICS INC worth?
INDAPTUS THERAPEUTICS INC (INDP) has a market capitalization of 4.52M USD. This makes INDP a Nano Cap stock.